Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
U16
i
Other names:
U16, CD20 specific CAR T, CART-20, CAR T-20, U 16, U-16
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Central South University, Shanghai Unicar
Drug class:
CD20-targeted CAR-T immunotherapy
Related drugs:
‹
IMPT-314 (2)
ADI-001 (1)
MB-106 (1)
JNJ-4496 (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
CAR-20/19-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART20 (0)
CBM-C20.1 (0)
CD19/CD20 CAR T-cells (0)
CD20-CART (0)
CD20-CD19 cCAR T cells (0)
ELC-301 (0)
JNJ-9530 (0)
KITE-363 (0)
LCAR-AIO (0)
LY007 (0)
MB-CART20.1 (0)
PBCAR 20A (0)
RG6540 (0)
UCART20x22 (0)
YTS101 (0)
autologous TriCAR T (0)
bbT369 (0)
multi-CAR-T cell therapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
MB-CART2019.1 (0)
IMPT-314 (2)
ADI-001 (1)
MB-106 (1)
JNJ-4496 (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
CAR-20/19-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART20 (0)
CBM-C20.1 (0)
CD19/CD20 CAR T-cells (0)
CD20-CART (0)
CD20-CD19 cCAR T cells (0)
ELC-301 (0)
JNJ-9530 (0)
KITE-363 (0)
LCAR-AIO (0)
LY007 (0)
MB-CART20.1 (0)
PBCAR 20A (0)
RG6540 (0)
UCART20x22 (0)
YTS101 (0)
autologous TriCAR T (0)
bbT369 (0)
multi-CAR-T cell therapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
MB-CART2019.1 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=100, Recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
over 1 year ago
New P1/2 trial
|
IL6 (Interleukin 6)
|
CD20 positive • CD20 negative
|
cyclophosphamide • U16
2years
Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. (PubMed, Discov Oncol)
The effective dose of CAR-T20 in mice starts from 1 × 10 per mouse, equivalent to a clinical dose of 5 × 10/kg. Together, our data support the clinical translation of CAR-T20 for R/R B-cell NHL patients.
2 years ago
Preclinical • Journal • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD20 expression
|
U16
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login